Chang Feng | Cancer Cell Biology | Best Researcher Award

Posted on 27/02/202527/02/2025 by sciencefather

Dr. Chang Feng | Cancer Cell Biology | Best Researcher Award

Dr. Chang Feng , Shanghai University , China

Chang Feng is a distinguished researcher in the fields of tumor molecular diagnosis, biosensing, and intelligent DNA. Born in Shanghai, China, on January 1, 1988, Chang Feng pursued a rigorous academic journey, completing his Ph.D. at Nanjing University (2015-2019) after earning his M.D. from Shanghai University (2012-2015). He is currently a lecturer at Shanghai University since 2019. Feng has contributed significantly to scientific advancements in cancer diagnostics, molecular biosensors, and cutting-edge DNA research. His works often involve the development of innovative detection techniques and the creation of novel DNA-based diagnostic systems. Feng has a collaborative approach, working with multiple researchers to achieve groundbreaking results. His publications in prestigious journals highlight his expertise in developing biosensors, RNA origami, and catalytic DNAzymes for biomedical applications.

Publication Profile:

Scopus

Strengths for the Award:

Chang Feng’s research is exceptional and well-suited for the Best Researcher Award. His expertise spans across tumor molecular diagnosis, biosensor development, and intelligent DNA systems. His contributions to cancer diagnostics, bioimaging, and biosensing technologies are groundbreaking. Feng has published several high-impact articles in leading journals, demonstrating significant advancements in DNAzymes, electrochemical biosensing, and RNA origami. His work in designing innovative DNA-based diagnostic platforms and cancer therapies reflects his ability to integrate chemistry, biology, and engineering, providing novel solutions for clinical applications. Feng’s interdisciplinary approach and leadership in the field have earned him numerous collaborations with researchers and institutions globally, further enhancing his credibility as a top-tier researcher.

Areas for Improvements:

While Feng has made remarkable contributions to scientific research, one area for improvement is expanding his focus to more clinical applications of his findings. Commercializing his biosensing technologies for real-world healthcare implementation would increase the practical impact of his work. Additionally, improving outreach through public science communication could help raise awareness of his advancements and engage a broader audience.

Education:

Chang Feng received his M.D. from Shanghai University in 2015, where he developed a strong foundation in molecular biology, diagnostics, and bioengineering. His doctoral journey continued at Nanjing University (2015-2019), where he obtained his Ph.D. focusing on tumor molecular diagnosis and biosensing technologies. During his time at Nanjing University, Feng’s research concentrated on the development of DNA-based biosensors and new methodologies for cancer detection. His education at these esteemed institutions provided him with the technical expertise necessary to pioneer groundbreaking research in the field of molecular diagnostics. Feng’s academic training involved rigorous coursework in molecular biology, chemical engineering, and bioinformatics, contributing significantly to his current work in bioimaging, biosensing, and the development of intelligent DNA systems.

Experience:

Chang Feng has a strong academic and research career, currently serving as a lecturer at Shanghai University since 2019. Prior to his current role, he earned his Ph.D. at Nanjing University (2015-2019) and M.D. from Shanghai University (2012-2015). Throughout his career, Feng has collaborated with leading researchers, contributing to the development of innovative biosensing technologies and cancer diagnostics. His work includes advancing DNA-based biosensors, DNAzyme probes, and other cutting-edge diagnostic tools. As a lecturer, Feng mentors graduate students and participates in academic teaching and research projects. He has been involved in several collaborative publications that have furthered the field of molecular biosensors, focusing on intelligent DNA-based systems and tumor detection methodologies. Feng’s research experience combines theoretical knowledge with practical applications, making him a recognized figure in the field of biosensor research and molecular diagnostics.

Research Focus:

Chang Feng’s primary research focus lies in tumor molecular diagnosis, biosensor development, and intelligent DNA systems. He is particularly interested in advancing technologies for cancer detection through the application of molecular biosensors, bioimaging, and intelligent DNA devices. His research explores the use of DNAzymes, catalytic DNA molecules, and RNA origami for targeted molecular detection, with a focus on enhancing the sensitivity and specificity of cancer diagnostics. Feng’s work also investigates the use of biosensors for the detection of small molecules, leveraging innovative electrochemical and fluorescence-based platforms. His interdisciplinary approach combines elements of chemistry, biology, and engineering to create advanced diagnostic systems with potential clinical applications. Feng is dedicated to improving the efficiency of diagnostic tools and is committed to developing more accurate and faster methods for early cancer detection and molecular analysis.

Publications Top Notes:

Single-cell analysis of highly metastatic circulating tumor cells by combining a self-folding induced release reaction with a cell capture microchip 🧬🔬 (Anal. Chem., 2021)
Hierarchical biomarkers detection via a universal polydopamine probe catalyzed by a hexagonal star-nanostructured DNAzyme 🔬🧪 (Sensor. Actuat. B-Chem., 2022)
Construction of a ternary complex based DNA logic nanomachine for a highly accurate imaging analysis of cancer cells 🧬💡 (ACS Sens., 2020)
Lantern-shaped flexible RNA origami for Smad4 mRNA delivery and growth suppression of colorectal cancer 🧬🦠 (Nat. Commun., 2023)
Liquid-colloid-solid modular assembly for three-dimensional electrochemical biosensing of small molecules 💧⚡ (Biosens. Bioelectron., 2024)
Dual-targets binding protection mediated rolling circle transcription with tandem fluorescent RNA aptamers for label-free detection of liver cancer biomarkers 🧬🦠 (Sensor. Actuat. B-Chem., 2024)
Cell-Free Biosensing Genetic Circuit Coupled with Ribozyme Cleavage Reaction for Rapid and Sensitive Detection of Small Molecules 🧬⚡ (ACS Synth. Biol., 2023)
A portable and partitioned DNA hydrogel chip for multitarget detection 💧🧬 (Lab Chip., 2023)

Conclusion:

Chang Feng’s research in tumor molecular diagnostics, biosensors, and intelligent DNA is truly cutting-edge. His scientific rigor, collaboration with top researchers, and groundbreaking discoveries in cancer detection and biosensing technologies make him a deserving candidate for the Best Researcher Award. By continuing to bridge the gap between laboratory research and clinical applications, Feng will likely have an even greater impact in advancing medical diagnostics and therapeutic strategies.

Renate Pichler | Cancer Cell Biology | Best Researcher Award

Posted on 07/02/202507/02/2025 by sciencefather

Assoc. Prof. Dr.Renate Pichler | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Renate Pichler , Medizinische Universität Innsbruck , Austria

Assoc. Prof. Renate Pichler, MD, PhD, FEBU, is a prominent urologist with a specialization in urological oncology at the Medical University of Innsbruck, Austria. She is the head of the uro-oncological research group, the uro-oncological tumor board, and the special uro-oncological outpatient clinic at the institution. A native of Bolzano, South Tyrol, Pichler holds Italian nationality and has made substantial contributions to cancer research, particularly in the areas of testicular and bladder cancer. She is fluent in German, English, and Italian. With over 170 publications, her research has gained significant attention, earning her an H-index of 32 and over 3,000 citations. She is actively involved in clinical practices, including complex surgeries for penile cancer and bladder cancer management. Pichler’s expertise and leadership make her a respected figure in uro-oncological care and research.

Publication Profile:

Orcid

Strengths for the Award:

Assoc. Prof. Renate Pichler’s exceptional qualifications and impressive career trajectory position her as an outstanding candidate for the Best Researcher Award. As a senior physician specializing in urological oncology at the Medical University of Innsbruck, she demonstrates profound expertise in critical areas such as penile and testicular cancer surgery, uro-oncological endourology, and minimal-invasive surgery. Her leadership roles in multiple uro-oncological research groups and tumor boards further highlight her capacity for both clinical practice and advancing the scientific field. With 172 publications, an H-index of 32, and notable citation impact, she has contributed significantly to urological oncology research. Her ongoing involvement in groundbreaking projects like the “LifeBoost” Cancer Mission lab and liquid biopsy in bladder cancer illustrates her drive for pioneering work.

Areas for Improvement:

Although Prof. Pichler has shown excellence in clinical research, expanding her work in cross-disciplinary collaborations, particularly with emerging technologies such as artificial intelligence in cancer diagnostics, could lead to even more transformative impacts in the field. This would expand her already impressive body of work and provide a broader technological foundation for uro-oncology.

Education:

Assoc. Prof. Renate Pichler’s educational journey started at the Medical University of Innsbruck, where she earned her medical degree (Dr. med. univ.) from 2002 to 2008. She further advanced her expertise by becoming a resident in urology at the Medical University of Innsbruck from 2008 to 2014. During this period, she joined the Urologic Oncology Study Group and contributed to multiple research initiatives. In addition to her medical training, Pichler pursued a Master of Science in Medical Writing (MSc.) at the same institution from 2010 to 2011, enhancing her scientific communication skills. Her education laid the foundation for her career in urological oncology and her commitment to advancing cancer treatment and patient care.

Experience:

Assoc. Prof. Renate Pichler has a distinguished career in urology with a specific focus on uro-oncology. After completing her residency at the Medical University of Innsbruck, she became a senior physician in the Department of Urology, where she now serves as the head of both the uro-oncological research group and the specialized uro-oncological outpatient clinic. Pichler’s clinical expertise includes complex surgeries such as penile cancer operations, radical and modified inguinal lymphadenectomies, as well as endourology and minimal-invasive uro-oncological surgeries. Her leadership in the Comprehensive Cancer Center Innsbruck (CCCI) involves coordinating multidisciplinary tumor boards for optimal treatment plans. Pichler’s vast experience also extends to research in urological oncology, focusing on innovative treatment strategies for bladder and testicular cancer, and overseeing critical studies and clinical trials. Her contributions have firmly established her as a leader in the field.

Awards and Honors:

Assoc. Prof. Renate Pichler has earned multiple prestigious awards throughout her career. Notably, she received the Best Poster Prize at the European Association of Urology (EAU) Congress in both 2011 and 2012, held in Vienna and Paris, respectively. Her exemplary work earned her the 2nd Prize for the Bayer Young Urology Oncology Award at the Annual Conference of the Austrian Society of Urology in 2013. In recognition of her outstanding contributions to the field, Pichler’s research and clinical expertise have also been acknowledged through various grants, including the 2024 “LifeBoost” Cancer Mission Lab grant from the Ludwig Boltzmann Gesellschaft (LBG) and the 2023 Merck KGaA grant for a study on liquid biopsy in bladder cancer. These awards and honors reflect her leadership, innovation, and commitment to improving patient care and advancing uro-oncological research.

Research Focus:

Assoc. Prof. Renate Pichler’s research focuses on advancing uro-oncology, particularly in the treatment of bladder and testicular cancers. Her work explores the molecular mechanisms of cancer, including the regulation of vitamin D metabolism in testicular cancer and the impact of BCG treatment on bladder cancer recurrence. Pichler is dedicated to improving treatment outcomes by investigating biomarkers and therapeutic targets, such as CXCR3 in renal cell carcinoma. She is also deeply involved in enhancing perioperative strategies for bladder cancer surgery and understanding the variations in cancer diagnosis and treatment, including the impact of seasonal factors. As the head of a research group and a multidisciplinary tumor board, her research bridges clinical care with cutting-edge scientific inquiry. Her expertise spans liquid biopsy, photodynamic diagnosis, and targeted therapy, with a strong focus on developing more effective, personalized treatment options for uro-oncological patients.

Publications Top Notes:

Perioperative Outcomes and Trends in Transurethral Resection of Bladder Tumors with Photodynamic Diagnosis 🌐📄
Variation in Follow-Up after Radical Cystectomy for Bladder Cancer 🔬💡
Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations 💉🩺
Isochromosome 12p Formation Regulates Vitamin D Metabolism in Testicular Cancer 🧬🔬
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Non-Muscle Invasive Bladder Cancers 💉📊
CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival in Renal Cell Carcinoma 🧫📈
HUS1 as a Potential Therapeutic Target in Urothelial Cancer 🔬🧪
Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors 🌞💡
The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer 🦠💔
Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure 🔬🚨

Conclusion:

Assoc. Prof. Renate Pichler’s combination of research excellence, clinical expertise, and leadership in urological oncology makes her an ideal candidate for the Best Researcher Award. Her contributions continue to shape the landscape of cancer treatment and diagnosis, ensuring better outcomes for patients worldwide. With a steady record of high-quality publications and successful grants, she exemplifies the dedication and innovation necessary to excel in the medical field.

Rika Sasaki | mitochondria | Best Researcher Award

Posted on 04/02/202504/02/2025 by sciencefather

Dr. Rika Sasaki | mitochondria | Best Researcher Award

Dr. Rika Sasaki , Department of Molecular Pathology, Nara Medical University , Japan

Rika Sasaki is a researcher in the Department of Molecular Pathology at Nara Medical University, Japan. She completed her degree in Medicine from the Faculty of Medicine, Nara Medical University in March 2023 and began her doctoral studies in April 2023. Currently, she is in the second year of her program, focusing on cancer research, particularly on the role of mitochondrial transfer in colorectal cancer. Rika is passionate about understanding the molecular mechanisms behind cancer malignancy and drug resistance. She has a growing academic presence, having published multiple papers in respected journals such as the International Journal of Molecular Sciences. Her work has contributed to important discoveries, including the identification of HMGB1 as a key factor in mitochondrial transfer. Rika is a member of The Japanese Cancer Association and The Japanese Society of Pathology, and she is dedicated to furthering cancer-related research.

Publication Profile:

Scopus

Strengths for the Award:

Rika Sasaki has demonstrated considerable promise as a young researcher in the field of molecular pathology, with a focused interest in cancer biology. Sasaki’s research on the therapeutic strategy for targeting drug resistance in colorectal cancer through mitochondrial transfer is both innovative and highly relevant. Her ability to identify key molecules, such as oxidized HMGB1, contributing to cancer malignancy and resistance, highlights her potential to shape future cancer therapies. Moreover, Sasaki’s publication record, including in high-impact journals, showcases the quality and impact of her work. Her membership in esteemed professional societies further strengthens her standing in the research community.

Areas for Improvement:

Although Sasaki is an emerging researcher with promising contributions, expanding her network through collaborative research and increasing the breadth of her publications could enhance her visibility in the scientific community. Additionally, the exploration of translational research, particularly through clinical applications, could be an important avenue for the future development of her work.

Education:

Rika Sasaki earned her degree in Medicine from the Faculty of Medicine at Nara Medical University in March 2023. Shortly after graduation, she enrolled in the Doctoral Program at Nara Medical University in April 2023. As of February 2025, she is in the second year of her Ph.D. studies. During her academic career, Rika has demonstrated a strong commitment to medical and scientific research. Her education has provided her with a solid foundation in molecular pathology, particularly with an emphasis on cancer biology. Rika’s research interests have led her to focus on understanding the intricate mechanisms of drug resistance in cancer cells, particularly in colorectal cancer. Her research findings are contributing to the development of potential therapeutic strategies, which may play a significant role in overcoming treatment resistance. Her academic journey reflects dedication, rigor, and a passion for advancing medical knowledge.

Experience:

Rika Sasaki’s professional journey as a researcher began after her graduation from Nara Medical University in March 2023, when she immediately began her Doctoral Program. As a second-year Ph.D. student, she has already been involved in groundbreaking research focused on cancer drug resistance mechanisms. Her experience includes working on the project titled “Therapeutic Strategy for Colorectal Cancer Targeting Drug Resistance Induced by Mitochondrial Transfer.” Rika’s research highlights the oxidized form of HMGB1 as a major factor in mitochondrial transfer, contributing to cancer cell stemness and drug resistance. She has also collaborated with a team of scientists, publishing several research articles in peer-reviewed journals. Though she does not have formal consultancy or industry experience yet, Rika’s academic achievements and publication record indicate her growing expertise in molecular pathology. She is currently refining her skills and knowledge, positioning herself as a future leader in cancer research.

Awards and Honors:

Rika Sasaki, while early in her career, has made significant strides in cancer research, particularly focusing on mitochondrial transfer and drug resistance in colorectal cancer. She has not yet received formal awards for her work; however, her research has been published in respected journals such as the International Journal of Molecular Sciences, underlining her scientific contributions. Rika’s H-index of 5 reflects the growing impact of her publications. Although she has not received awards such as the Best Researcher Award yet, her innovative work has attracted recognition within her institution and the scientific community. As her research progresses, particularly in understanding cancer drug resistance, Rika is likely to gain more recognition in the coming years. Her academic commitment and contributions to molecular pathology have earned her membership in notable professional societies like The Japanese Cancer Association and The Japanese Society of Pathology, setting her up for future accolades.

Research Focus:

Rika Sasaki’s research primarily revolves around understanding cancer drug resistance, particularly in colorectal cancer. Her focus is on the therapeutic strategy targeting mitochondrial transfer that promotes cancer cell stemness and resistance to conventional chemotherapy. Through her research, she has identified the oxidized form of HMGB1 as a key factor that accelerates mitochondrial transfer from mesenchymal stem cells to colorectal cancer cells. This discovery holds potential for novel cancer therapies aimed at reversing drug resistance. Rika’s research also extends to studying energy metabolism and the role of various molecules, such as lauric acid, in overcoming chemoresistance. Her work provides critical insights into the molecular mechanisms underlying the malignancy of cancer cells, contributing to the development of more effective treatments. Rika’s research bridges molecular pathology and clinical applications, making her a promising scientist in the fight against cancer. Her findings are already influencing the field of cancer research, making her work highly relevant.

Publications Top Notes:

Oxidative stress

“Oxidative High Mobility Group Box-1 Accelerates Mitochondrial Transfer from Mesenchymal Stem Cells to Colorectal Cancer Cells Providing Cancer Cell Stemness” (Int. J. Mol. Sci. 2025) 📚💥
“Energy Metabolism and Stemness and the Role of Lauric Acid in Reversing 5-Fluorouracil Resistance in Colorectal Cancer Cells” (Int. J. Mol. Sci. 2025) 🍏🔬
“Significance of CD10 for Mucosal Immunomodulation by β-Casomorphin-7 in Exacerbation of Ulcerative Colitis” (Curr. Issues Mol. Biol. 2024) 🔬🧬
“Effects of High-Mobility Group Box-1 on Mucosal Immunity and Epithelial Differentiation in Colitic Carcinoma” (Int. J. Mol. Sci. 2024) 🔬🦠
“Berberine Improves Cancer-Derived Myocardial Impairment in Experimental Cachexia Models by Targeting High-Mobility Group Box-1” (Int. J. Mol. Sci. 2024) 💪🧪
“Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma” (Int. J. Mol. Sci. 2024) 💥🧠
“Investigation of Cancer-Induced Myocardial Damage in Autopsy Cases—A Comparison of Cases with and without Chemotherapy” (Pathol. Int. 2024) 🧠❤️
“Pterostilbene Induces Apoptosis from Endoplasmic Reticulum Stress Synergistically with Anticancer Drugs That Deposit Iron in Mitochondria” (Int. J. Mol. Sci. 2024) 🧪💔
“Involvement of Ferroptosis Induction and Oxidative Phosphorylation Inhibition in the Anticancer-Drug-Induced Myocardial Injury: Ameliorative Role of Pterostilbene” (Int. J. Mol. Sci. 2024) ⚡🧬
“Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma” (Int. J. Mol. Sci. 2023) 🧪🍃

Conclusion:

Given her strong academic background, innovative research on cancer biology, and growing publication record, Rika Sasaki is a strong candidate for the Best Researcher Award. Her work on mitochondrial transfer and cancer resistance mechanisms promises significant advancements in cancer treatment. With continued professional growth and wider collaborations, she has the potential to make substantial contributions to medical science.

Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Posted on 06/01/202506/01/2025 by sciencefather

Prof. Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Prof. Yimin Zhu , Suzhou Institute of Nanotechnology, Chinese Academy of Sciences , China

Prof. Yimin Zhu is a distinguished researcher in bioengineering, specializing in cancer therapies, biomaterials, and peptide screening platforms. With a background in both clinical medicine and biotechnology, she bridges the gap between medical applications and cutting-edge biotechnological innovations. Prof. Zhu completed her master’s in Clinical Medicine from Tianjin Medical University in 1996 and a Ph.D. in Biochemistry from the National University of Singapore in 2005. She has made significant contributions to cancer immunotherapy, drug delivery systems, and biomarker identification. Prof. Zhu’s work has led to over 30 first-author/co-corresponding publications in leading scientific journals, and she holds more than 20 patents. She currently holds a professorship at Suzhou Institute of Nano-Tech and Nano-Bionics, CAS, where her research continues to advance cancer treatments through novel molecular mechanisms and drug delivery platforms.

Publication Profile:

Scopus

Strengths for the Award:

Interdisciplinary Expertise: Prof. Yimin Zhu has a unique blend of clinical medicine and advanced biotechnology expertise, making her well-suited to bridge the gap between medical practice and cutting-edge cancer research. Her background in both the clinical and research fields allows her to tackle cancer therapies from multiple angles.
Impactful Research: Prof. Zhu’s research focuses on critical areas in cancer therapy, such as peptide-based immunotherapy, tumor mechanisms, drug delivery systems, and biomarker discovery. She has published over 30 high-impact papers in leading journals, showcasing her leadership in the field.
Innovative Contributions: She has made substantial contributions to developing peptide-based bispecific CAR T cells and innovative drug delivery systems, with several patents granted. These innovations hold great promise for advancing cancer therapy and improving patient outcomes.
Support and Funding: Prof. Zhu has successfully secured substantial research funding, including multiple grants from the National Natural Science Foundation of China, supporting her groundbreaking research in cancer immunotherapy and biomaterial development.

Areas for Improvement:

Broader Outreach: Although Prof. Zhu has made impressive advancements in cancer research, expanding her work’s visibility to a broader audience in the medical and biotechnology communities, as well as among the general public, could increase the impact of her innovations.
Collaboration and Mentorship: Further expanding interdisciplinary collaborations, particularly with social scientists or clinicians in oncology, could strengthen the practical application of her research and increase its translation into clinical practice. Additionally, mentoring young women in STEM could increase her contribution to fostering diversity in the field.
Public Engagement: Enhancing communication efforts to present her research in a more accessible format for non-experts could be a significant avenue for impact, particularly in terms of attracting additional funding and public interest in her cancer-focused work.

Education:

Prof. Yimin Zhu’s educational journey reflects her interdisciplinary approach to bioengineering and medical science. She earned her Master’s degree in Clinical Medicine from Tianjin Medical University in 1996, where she initially focused on medical practice, gaining hands-on experience as a resident and consultant in Neurology. Her passion for scientific research led her to pursue a Ph.D. in Biochemistry from the National University of Singapore, completed in 2005. This transition to biochemistry allowed her to explore molecular biology, cancer research, and biotechnology. Prof. Zhu’s postdoctoral work at the University of California, Santa Barbara, in Chemical Engineering, further honed her expertise in nanotechnology, bioengineering, and therapeutic innovations. This broad educational foundation, combining clinical experience with cutting-edge research, has uniquely positioned her as a leader in cancer bioengineering and drug delivery systems.

Experience:

Prof. Yimin Zhu’s diverse experience spans both clinical medicine and high-impact research. Between 1996 and 2000, she worked as a resident and consultant doctor in Neurology, which provided a strong foundation in patient care and medical science. Transitioning to research, she served as a research fellow at the National University of Singapore from 2003 to 2005, focusing on biochemistry and cancer-related molecular mechanisms. Prof. Zhu further developed her expertise during her postdoctoral training in the Chemical Engineering Department at the University of California, Santa Barbara, where she explored the intersection of chemical engineering, nanotechnology, and therapeutic interventions. Since joining the Suzhou Institute of Nano-Tech and Nano-Bionics in 2008, she has been a professor, where she leads innovative research in peptide-based cancer therapies, immunotherapy, and drug delivery systems. Her extensive academic background and practical experience have earned her numerous patents and substantial research funding.

Research Focus:

Prof. Yimin Zhu’s research primarily focuses on bioengineering for cancer treatment, peptide screening platforms, and targeted drug delivery systems. Her work involves identifying molecular mechanisms behind tumor cell behavior and developing innovative methods for cancer diagnosis and therapy. She is dedicated to advancing cancer immunotherapy, particularly through the development of peptide-based bispecific CAR T cells targeting key proteins like EGFR and tumor stroma. Prof. Zhu’s research aims to enhance the efficacy of cancer treatments while minimizing side effects. Her studies also explore the development of smart delivery systems, such as extracellular vesicle-based nanodrugs, to improve the precision and effectiveness of drug delivery to tumor sites. Additionally, her work delves into the identification of cancer biomarkers, offering new ways to predict tumor metastasis and optimize treatment regimens. By combining molecular biology, nanotechnology, and biotechnology, Prof. Zhu’s research holds great promise for advancing personalized cancer care.

Publications Top Notes:

The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy 🧬
Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress 💉
Natural killer cells contribute to ‘hot’ tumor regression in the allergic inflammatory environment 🦠
Identification of cancer protein biomarker based on cell specific peptide and its potential role in predicting tumor metastasis 🔬
Extracellular Vesicle‐Based Nanodrug Delivery 💊
Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin 🧫
Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity 🌿
Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety 🦠
Smart delivery of poly-peptide composite for effective cancer therapy 💡
The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells ⚙️

Conclusion:

Prof. Yimin Zhu’s research excellence, particularly in cancer therapy, peptide-based immunotherapy, and novel drug delivery systems, positions her as a highly deserving candidate for the Research for Women Researcher Award. Her interdisciplinary approach, groundbreaking innovations, and leadership in publishing high-impact scientific papers make her a trailblazer in the field of bioengineering. By addressing the areas for improvement, particularly in outreach and mentorship, Prof. Zhu could amplify her contributions even further, inspiring the next generation of women scientists and advancing the fight against cancer.